BiotechTube
Surface Ophthalmics

Surface Ophthalmics

San Diego, United States· Est.
surfaceophthalmics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $33M

Overview

Surface Ophthalmics is a private, pre-revenue biotech targeting the large and underserved dry eye disease market. The company has advanced three proprietary drug candidates through Phase II clinical trials involving over 550 patients, positioning itself to address a spectrum of DES presentations from episodic to chronic. Led by a team with deep ophthalmology experience, including founder Dr. Richard Lindstrom, Surface aims to provide eyecare professionals with a multi-faceted suite of treatments targeting signs, symptoms, and underlying causes of DES.

OphthalmologyDry Eye Syndrome

Technology Platform

Proprietary formulation science for topical ophthalmic solutions, developing both Rx and OTC candidates targeting specific dry eye pathophysiology.

Funding History

2
Total raised:$33M
Series A$25M
Seed$8M

Opportunities

The dry eye market is large, under-diagnosed, and characterized by poor patient persistence with current therapies, indicating high unmet need.
Surface's strategy of offering a comprehensive portfolio (Rx and OTC) for diverse DES presentations could capture significant market share across the treatment spectrum.
The post-surgical ocular surface market provides an additional, predictable growth avenue.

Risk Factors

The company faces significant clinical development risk as its value is tied to three unapproved candidates.
As a pre-revenue private firm, securing funding for costly Phase III trials and commercialization is a major hurdle.
It must also differentiate and compete in a market with established players.

Competitive Landscape

The dry eye therapeutic market is competitive, featuring large players like Allergan (Restasis), Novartis (Xiidra), Bausch + Lomb (Miebo), and Sun Pharmaceutical (Cequa). Competition is based on efficacy, safety, dosing convenience, and cost. Surface's potential advantage lies in its targeted formulations and a portfolio approach designed to address specific patient sub-types.

More companies in Small Molecule Drugs →More companies in United States →